{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T22:07:51Z","timestamp":1775254071332,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"DOI":"10.1007\/s40292-023-00579-0","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T14:03:15Z","timestamp":1683900195000},"page":"265-279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Discontinuation of Antihypertensive Drug Use Compared to Continuation in COVID-19 Patients: A Systematic Review with Meta-analysis and Trial Sequential Analysis"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3904-7514","authenticated-orcid":false,"given":"Diego","family":"Chambergo-Michilot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4045-0260","authenticated-orcid":false,"given":"Fernando M.","family":"Runzer-Colmenares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7859-8466","authenticated-orcid":false,"given":"Pedro A.","family":"Segura-Salda\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"key":"579_CR1","unstructured":"Coronavirus Resource Center, Johns Hopkins University Maps & Trends [accessed on January 1 2022]. Available from https:\/\/www.coronavirus.jhu.edu\/map.html."},{"issue":"2","key":"579_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/jch.14417","volume":"24","author":"B Bepouka","year":"2022","unstructured":"Bepouka B, Situakibanza H, Sangare M, Mandina M, Mayasi N, Longokolo M, et al. Mortality associated with COVID-19 and hypertension in sub\u2010Saharan Africa. A systematic review and meta\u2010analysis. J Clin Hypertens. 2022;24(2):99.","journal-title":"J Clin Hypertens"},{"issue":"1","key":"579_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2478\/jtim-2021-0011","volume":"9","author":"J Gong","year":"2021","unstructured":"Gong J, Sun Y, Xie L. ACEI\/ARB drug therapy in COVID-19 patients: yes or no? J Transl Int Med. 2021;9(1):8\u201311.","journal-title":"J Transl Int Med"},{"key":"579_CR4","doi-asserted-by":"publisher","first-page":"103749","DOI":"10.1016\/j.compbiomed.2020.103749","volume":"121","author":"B Robson","year":"2020","unstructured":"Robson B. COVID-19 coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles\u2019 heel conserved region to minimize probability of escape mutations and drug resistance. Comput Biol Med. 2020;121:103749.","journal-title":"Comput Biol Med"},{"key":"579_CR5","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1186\/s13054-020-03195-9","volume":"24","author":"CL Onweni","year":"2020","unstructured":"Onweni CL, Zhang YS, Caulfield T, Hopkins CE, Fairweather DL, Freeman WD. ACEI\/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking. Crit Care. 2020;24:475.","journal-title":"Crit Care"},{"key":"579_CR6","doi-asserted-by":"crossref","unstructured":"Gavriilaki E, Anyfanti P, Gavriilaki M, Lazaridis A, Douma S, Gkaliagkousi E. Endothelial dysfunction in COVID-19: lessons learned from coronaviruses. Curr Hypertens Rep. 2020;22(9):63.","DOI":"10.1007\/s11906-020-01078-6"},{"issue":"5","key":"579_CR7","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/HJH.0000000000002450","volume":"38","author":"M Esler","year":"2020","unstructured":"Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens. 2020;38(5):781\u20132.","journal-title":"J Hypertens"},{"issue":"1","key":"579_CR8","doi-asserted-by":"publisher","first-page":"147032032098711","DOI":"10.1177\/1470320320987118","volume":"22","author":"A Harky","year":"2021","unstructured":"Harky A, Chor CYT, Nixon H, Jeilani M. The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients. J Renin Angiotensin Aldosterone Syst. 2021;22(1):1470320320987118.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"1","key":"579_CR9","first-page":"1","volume":"108","author":"B Sz\u00e9k\u00e1cs","year":"2021","unstructured":"Sz\u00e9k\u00e1cs B, V\u00e1rb\u00edr\u00f3 S, Debreczeni L. High-dose ACEi might be harmful in COVID-19 patients with serious respiratory distress syndrome by leading to excessive bradykinin receptor activation. Physiol Int. 2021;108(1):1\u20139.","journal-title":"Physiol Int"},{"key":"579_CR10","doi-asserted-by":"crossref","unstructured":"Villa-Zapata L, Carhart BS, Horn JR, Hansten PD, Subbian V, Gephart S et al. Serum potassium changes due to concomitant ACEI\/ARB and spironolactone therapy: a systematic review and meta-analysis. Am J Health Syst Pharm. 2021;78(24):2245\u201355.","DOI":"10.1093\/ajhp\/zxab215"},{"issue":"4","key":"579_CR11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1177\/1715163520929373","volume":"153","author":"StJMH Barry","year":"2020","unstructured":"Barry St JMH. COVID-19 and the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Can Pharm J (Ott). 2020;153(4):193\u20137.","journal-title":"Can Pharm J (Ott)"},{"key":"579_CR12","doi-asserted-by":"crossref","unstructured":"Oussalah A, Gleye S, Clerc Urmes I, Laugel E, Callet J, Barb\u00e9 F et al. Long-term ACE inhibitor\/ARB use is associated with severe renal dysfunction and acute kidney injury in patients with severe COVID-19: results from a referral center cohort in the Northeast of France. Clin Infect Dis. 2020;71(9):2447\u201356.","DOI":"10.1093\/cid\/ciaa677"},{"issue":"6","key":"579_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jiph.2021.03.004","volume":"14","author":"AA Alrashed","year":"2021","unstructured":"Alrashed AA, Khan TM, Alhusseini NK, Asdaq SMB, Enani M, Alosaimi B, et al. Severity of COVID-19 infection in ACEI\/ARB users in specialty hospitals: a retrospective cohort study. J Infect Public Health. 2021;14(6):726\u201333.","journal-title":"J Infect Public Health"},{"key":"579_CR14","doi-asserted-by":"publisher","first-page":"111469","DOI":"10.1016\/j.biopha.2021.111469","volume":"138","author":"G De Luca","year":"2021","unstructured":"De Luca G, Cercek M, Okkels Jensen L, Bushljetikj O, Calmac L, Johnson T, et al. Impact of renin-angiotensin system inhibitors on mortality during the COVID pandemic among STEMI patients undergoing mechanical reperfusion: insight from an international STEMI registry. Biomed Pharmacother. 2021;138:111469.","journal-title":"Biomed Pharmacother"},{"key":"579_CR15","volume-title":"ACE inhibitors. En: StatPearls","author":"A Goyal","year":"2021","unstructured":"Goyal A, Cusick AS, Thielemier B. ACE inhibitors. En: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021."},{"issue":"2","key":"579_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/ehjcvp\/pvaa064","volume":"7","author":"A Grover","year":"2021","unstructured":"Grover A, Oberoi M. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Eur Heart J Cardiovasc Pharmacother. 2021;7(2):148\u201357.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"579_CR17","doi-asserted-by":"crossref","unstructured":"Xu J, Teng Y, Shang L, Gu X, Fan G, Chen Y et al. The effect of prior angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment on coronavirus disease 2019 (COVID-19) susceptibility and outcome: a systematic review and meta-analysis. Clin Infect Dis. 2021;72(11):e901\u201313.","DOI":"10.1093\/cid\/ciaa1592"},{"key":"579_CR18","doi-asserted-by":"publisher","first-page":"609857","DOI":"10.3389\/fcvm.2021.609857","volume":"8","author":"XC Dai","year":"2021","unstructured":"Dai XC, An ZY, Wang ZY, Wang ZZ, Wang YR. Associations between the use of renin-angiotensin system inhibitors and the risks of severe COVID-19 and mortality in COVID\u2009-19 patients with hypertension: a meta-analysis of observational studies. Front Cardiovasc Med. 2021;8:609857.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"579_CR19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336\u201341.","journal-title":"Int J Surg"},{"key":"579_CR20","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, eds. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane, 2022 [accessed on January 1 2022]. Available from https:\/\/www.training.cochrane.org\/handbook."},{"key":"579_CR21","doi-asserted-by":"publisher","unstructured":"Chambergo-Michilot D, Runzer-Colmenares FM, Salda\u00f1a PAS. Proyecto de tesis: Descontinuaci\u00f3n del uso de f\u00e1rmacos antihipertensivos comparado a la continuaci\u00f3n en pacientes con COVID-19: una revisi\u00f3n sistem\u00e1tica con meta-an\u00e1lisis y an\u00e1lisis secuencial de ensayos cl\u00ednicos. May 2021.\u00a0https:\/\/doi.org\/10.6084\/m9.figshare.14526663.v1.","DOI":"10.6084\/m9.figshare.14526663.v1"},{"key":"579_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2288-14-45","volume":"14","author":"CKL Lo","year":"2014","unstructured":"Lo CKL, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med Res Methodol. 2014;14:45.","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"579_CR23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1164","volume":"7","author":"AA Veroniki","year":"2016","unstructured":"Veroniki AA, Jackson D, Viechtbauer W, et al. Methods to estimate the between-study 2 variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7(1):55\u201379.","journal-title":"Res Synth Methods"},{"key":"579_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JPA, Borm GF. The Hartung\u2013Knapp\u2013Sidik\u2013Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25.","journal-title":"BMC Med Res Methodol"},{"issue":"7414","key":"579_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"7109","key":"579_CR26","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"5","key":"579_CR27","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.3390\/ijerph20054088","volume":"20","author":"CL Yu","year":"2023","unstructured":"Yu CL, Carvalho AF, Thompson T, Tsai TC, Tseng PT, Hsu CW, et al. Trial sequential analysis and updated meta-analysis of fluvoxamine on clinical deterioration in adult patients with symptomatic COVID-19 infection. Int J Environ Res Public Health. 2023;20(5):4088.","journal-title":"Int J Environ Res Public Health"},{"issue":"3","key":"579_CR28","doi-asserted-by":"publisher","first-page":"101202","DOI":"10.1016\/j.accpm.2023.101202","volume":"42","author":"P Bellaver","year":"2023","unstructured":"Bellaver P, Schaeffer AF, Leitao CB, Rech TH, Nedel WL. Association between neuromuscular blocking agents and the development of intensive care unit-acquired weakness (ICU-AW): a systematic review with meta-analysis and trial sequential analysis. Anaesth Crit Care Pain Med. 2023;42(3):101202.","journal-title":"Anaesth Crit Care Pain Med"},{"issue":"4","key":"579_CR29","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1097\/MJT.0000000000001402","volume":"28","author":"A Bryant","year":"2021","unstructured":"Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, et al. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. Am J Ther. 2021;28(4):e434.","journal-title":"Am J Ther"},{"issue":"4","key":"579_CR30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394.","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"579_CR31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jama.2020.25864","volume":"325","author":"RD Lopes","year":"2021","unstructured":"Lopes RD, Macedo AVS, de Barros E, Silva PGM, Moll-Bernardes RJ, dos Santos TM, Mazza L, et al. Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: a randomized clinical trial. JAMA. 2021;325(3):254.","journal-title":"JAMA"},{"key":"579_CR32","doi-asserted-by":"crossref","unstructured":"Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C et al. Continuation versus discontinuation of renin\u2013angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med. 2021;9(3):275\u201384.","DOI":"10.1016\/S2213-2600(20)30558-0"},{"key":"579_CR33","doi-asserted-by":"crossref","unstructured":"Bauer A, Schreinlechner M, Sappler N, Dolejsi T, Tilg H, Aulinger BA et al. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet Respir Med. 2021;9(8):863\u201372.","DOI":"10.1016\/S2213-2600(21)00214-9"},{"issue":"6","key":"579_CR34","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ehjcvp\/pvaa056","volume":"6","author":"F Cannata","year":"2020","unstructured":"Cannata F, Chiarito M, Reimers B, Azzolini E, Ferrante G, My I, et al. Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality. Eur Heart J Cardiovasc Pharmacother. 2020;6(6):412\u20134.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"8","key":"579_CR35","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1093\/infdis\/jiaa447","volume":"222","author":"KW Lam","year":"2020","unstructured":"Lam KW, Chow KW, Vo J, Hou W, Li H, Richman PS, et al. Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome. J Infect Dis. 2020;222(8):1256\u201364.","journal-title":"J Infect Dis"},{"issue":"1","key":"579_CR36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12916-021-01992-9","volume":"19","author":"FJ de Abajo","year":"2021","unstructured":"de Abajo FJ, Rodr\u00edguez-Miguel A, Rodr\u00edguez-Mart\u00edn S, Lerma V, Garc\u00eda-Lled\u00f3 A, de Abajo FJ, et al. Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: a retrospective cohort study. BMC Med. 2021;19(1):118.","journal-title":"BMC Med"},{"issue":"12","key":"579_CR37","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.3390\/jcm10122642","volume":"10","author":"E Roy-Vallejo","year":"2021","unstructured":"Roy-Vallejo E, S\u00e1nchez Purificaci\u00f3n A, Torres Pe\u00f1a JD, S\u00e1nchez Moreno B, Arnalich F, Garc\u00eda Blanco MJ, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers withdrawal is associated with higher mortality in hospitalized patients with COVID-19. J Clin Med. 2021;10(12):2642.","journal-title":"J Clin Med"},{"issue":"8","key":"579_CR38","doi-asserted-by":"publisher","first-page":"801","DOI":"10.34067\/KID.0003792020","volume":"1","author":"I Chaudhri","year":"2020","unstructured":"Chaudhri I, Koraishy FM, Bolotova O, Yoo J, Marcos LA, Taub E, et al. Outcomes associated with the use of renin-angiotensin-aldosterone system blockade in hospitalized patients with SARS-CoV-2 infection. Kidney360. 2020;1(8):801\u20139.","journal-title":"Kidney360"},{"key":"579_CR39","doi-asserted-by":"crossref","unstructured":"Zhang X, Yu J, Pan L-Y, Jiang H-Y. ACEI\/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis. Pharmacol Res. 2020;158:104927.","DOI":"10.1016\/j.phrs.2020.104927"},{"key":"579_CR40","doi-asserted-by":"crossref","unstructured":"Baral R, White M, Vassiliou VS. Effect of renin-angiotensin-aldosterone system inhibitors in patients with COVID-19: a systematic review and meta-analysis of 28,872 patients. Curr Atheroscler Rep. 2020;22(10):61.","DOI":"10.1007\/s11883-020-00880-6"},{"key":"579_CR41","doi-asserted-by":"crossref","unstructured":"Patoulias D, Katsimardou A, Stavropoulos K, Imprialos K, Kalogirou MS, Doumas M. Renin-angiotensin system inhibitors and COVID-19: a systematic review and meta-analysis. Evidence for significant geographical disparities. Curr Hypertens Rep. 2020;22(11):90.","DOI":"10.1007\/s11906-020-01101-w"},{"issue":"4","key":"579_CR42","doi-asserted-by":"publisher","first-page":"147032032098132","DOI":"10.1177\/1470320320981321","volume":"21","author":"Y Xue","year":"2020","unstructured":"Xue Y, Sun S, Cai J, Zeng L, Wang S, Wang S, et al. Effects of ACEI and ARB on COVID-19 patients: a meta-analysis. J Renin Angiotensin Aldosterone Syst. 2020;21(4):1470320320981321.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"579_CR43","doi-asserted-by":"crossref","unstructured":"Gallo G, Volpe M, Savoia C. Endothelial Dysfunction in hypertension: current concepts and clinical implications. Front Med. 2022;8:798958.","DOI":"10.3389\/fmed.2021.798958"},{"key":"579_CR44","unstructured":"Khateri S, Mohammadi H, Khateri R, Moradi Y. The prevalence of underlying diseases and comorbidities in COVID-19 patients; an updated systematic review and meta-analysis. Arch Acad Emerg Med. 2020;8(1):e72."},{"issue":"1","key":"579_CR45","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s12325-021-01939-9","volume":"39","author":"T Har\u0119\u017clak","year":"2022","unstructured":"Har\u0119\u017clak T, Religioni U, Szyma\u0144ski FM, Hering D, Bara\u0144ska A, Neumann-Podczaska A, et al. Drug interactions affecting kidney function: beware of health threats from triple whammy. Adv Ther. 2022;39(1):140.","journal-title":"Adv Therapy"},{"key":"579_CR46","doi-asserted-by":"crossref","unstructured":"Abu Esba LC, Alqahtani RA, Thomas A, Shamas N, Alswaidan L, Mardawi G. Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort study. Infect Dis Ther. 2021;10(1):253\u201368.","DOI":"10.1007\/s40121-020-00363-w"},{"key":"579_CR47","unstructured":"NICE. Factors for decision making: COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19: advice. https:\/\/www.nice.org.uk\/advice\/es24\/chapter\/Factors-for-decision-making."},{"issue":"5","key":"579_CR48","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40292-020-00407-9","volume":"27","author":"M Volpe","year":"2020","unstructured":"Volpe M, Gallo G. COVID-19 and the forgotten majority. High Blood Press Cardiovasc Prev. 2020;27(5):339.","journal-title":"High Blood Press Cardiovasc Prev"}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-023-00579-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-023-00579-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-023-00579-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T04:58:25Z","timestamp":1685509105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-023-00579-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["579"],"URL":"https:\/\/doi.org\/10.1007\/s40292-023-00579-0","relation":{},"ISSN":["1179-1985"],"issn-type":[{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"16 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}